• Indaptus Therapeutics priced a private placement of 20,000,000 common shares at USD 0.6 each.
• Gross proceeds totaled about USD 12 million; no commissions were paid.
• Transaction closed June 17, 2026; shares sold to non-U.S. accredited investors in an unregistered offering under Regulation S.
• Investors received resale registration rights; a registration statement is due within 90 days, effectiveness targeted within 75 days of filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029918), on June 24, 2026, and is solely responsible for the information contained therein.